N-Terminal Pro-Brain Natriuretic Peptide in Arterial Hypertension: A Valuable Prognostic Marker of Cardiovascular Events

N-terminal pro-brain natriuretic peptide (NT-proBNP) provides important prognostic information in patients with chronic heart failure and in the general population. The aim of this study was to evaluate NT-proBNP as a prognostic marker of cardiovascular morbidity and death in a sample of subjects wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiac failure 2005-06, Vol.11 (5), p.S70-S75
Main Authors: Pedersen, Frants, Raymond, Ilan, Kistorp, Caroline, Sandgaard, Niels, Jacobsen, Peter, Hildebrandt, Per
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biomarkers - blood
Blood Pressure Monitors
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
cardiovascular risk
Echocardiography
Electrocardiography
Female
Follow-Up Studies
Humans
Hypertension
Hypertension - blood
Hypertension - diagnosis
Hypertension - physiopathology
Male
Middle Aged
Natriuretic Peptide, Brain - blood
natriuretic peptides
Patient Selection
Peptide Fragments - blood
Prognosis
Stroke Volume - physiology
Surveys and Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:N-terminal pro-brain natriuretic peptide (NT-proBNP) provides important prognostic information in patients with chronic heart failure and in the general population. The aim of this study was to evaluate NT-proBNP as a prognostic marker of cardiovascular morbidity and death in a sample of subjects with hypertension and preserved left ventricular systolic function from the general population. The study population was recruited from 4 general practitioners. The study participants (n = 569 subjects; ages, 50-89 years) completed a heart failure questionnaire and were submitted to blood pressure measurement, electrocardiography, echocardiography, and blood sampling. After exclusion of subjects with left ventricular ejection fraction of 150/90 mm Hg. During 3 years of follow-up, 28 subjects (10.4%) reached the composite end point of death, stroke/transient ischemic attack, or myocardial infarction. After adjustment for cardiovascular risk factors, NT-proBNP (logarithmically transformed) independently predicted the risk of experiencing a composite end point (hazard ratio, 1.94; P < .0001), and death (hazard ratio, 2.28; P < .0001). The risk of having a composite end point (21 vs 7; P = .005) was significantly higher for subjects with NT-proBNP above the study median than for subjects with NT-proBNP below the study median. In this sample of subjects with hypertension and preserved left ventricular systolic function from the general population, plasma NT-proBNP was found to be a valuable cardiovascular risk marker, independently of traditional risk factors and prevalent cardiovascular disease.
ISSN:1071-9164
1532-8414
DOI:10.1016/j.cardfail.2005.04.015